Worcester-based RXi Pharmaceuticals Corp. has named Anastasia Khvorova as Chief Scientific Officer, a newly created position for the company.
Khvorova previously held the same position at Dharmacon Inc., a division of Thermo Fisher Scientific and a developer and supplier of RNAi compounds. Before joining Dharmacon, she was a research scientist at Amgen, where she worked on the development of RNAi technology.
RNAi, which was pioneered by RXi co-founder, UMass Medical School professor and Nobel Prize winner Craig Mello, intends to treat diseases by interfering with the genes suspected of causing those diseases.
